Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.

Human pathology - 1 Mar 2018

Yamamoto Hidetaka, Iwasaki Takeshi, Yamada Yuichi, Matsumoto Yoshihiro, Otsuka Hiroshi, Yoshimoto Masato, Kohashi Kenichi, Taguchi Kenichi, Yokoyama Ryohei, Nakashima Yasuharu, Oda Yoshinao

Abstract excerpt

Giant cell tumors of bone (GCTBs) are characterized by mononuclear stromal cells and osteoclast-like giant cells; up to 95% have H3F3A gene mutation. The RANKL inhibitor denosumab, when used for the treatment of GCTB, leads to histological changes such as new bone formation and giant cell depletion. Here we assessed the diagnostic utility of immunohistochemical staining with the antibodies against histone H3.3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Histones

Share to Immunohistochemistry

Share to Mutation

Source

Identifiers

PMID: 29241742
DOI: 10.1016/j.humpath.2017.11.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.PMID 29241742Read ↗

Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.Semantic proximity Read ↗

H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.Semantic proximity Read ↗

H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.Semantic proximity Read ↗

H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases.Semantic proximity Read ↗

Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.Semantic proximity Read ↗

Reliability and Role of Mutation-specific H3F3A (Histone 3-3) G34W Immunohistochemistry to Differentiate Giant Cell Tumor of Bone From its Clinicoradiologic and Histologic Mimics: An Institutional Study.Semantic proximity Read ↗

Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimicsSemantic proximity Read ↗

H3-3A gene mutation analysis in giant cell tumor of bone and its histologic mimics: A single institutional study from India.Semantic proximity Read ↗

Giant cell tumor of bone: updated molecular pathogenesis and tumor biology.Semantic proximity Read ↗

Diagnostic Utility of Genetic and Immunohistochemical H3-3A Mutation Analysis in Giant Cell Tumour of Bone.Semantic proximity Read ↗

H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.Semantic proximity Read ↗

Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.